Statistics

Total Visits

Views
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study28

Select a period of time:

Number of views in the range

Views
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study19

Views

Views
October 20240
November 20240
December 20240
January 20250
February 20254
March 202515
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States3
Germany1
 

Top cities views

Views
Los Angeles1